Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2020 07:30 ET | Source: Biogen Inc.

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)

In the long-term follow-up study of Zolgensma® and real-world experience, it has been reported that some patients previously treated with gene therapy have been treated with SPINRAZA1,2,3The RESPOND...
July 08, 2020 17:01 ET | Source: Biogen Inc.

The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS

Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative diseaseFinal...
July 08, 2020 07:30 ET | Source: Biogen Inc.

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease

If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and TOKYO, July 08, 2020 (GLOBE NEWSWIRE) --...
June 10, 2020 07:30 ET | Source: Biogen Inc.

New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment

After up to 4.8 years of continuous treatment with SPINRAZA, 100 percent of children treated pre-symptomatically were alive, and none require permanent ventilationPatients continued to maintain and...
June 04, 2020 07:30 ET | Source: Biogen Inc.

Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020

Full analysis of the CLE part of the LILAC study reinforces positive top-line results; participants who received BIIB059 (anti-BDCA2) demonstrated statistically significant reduction of disease...
May 28, 2020 07:30 ET | Source: Biogen Inc.

Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science

The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson’s disease, Alzheimer’s disease and multiple...
May 19, 2020 07:30 ET | Source: Biogen Inc.

New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS

Patients treated with VUMERITY® (diroximel fumarate) and TECFIDERA® (dimethyl fumarate) showed a significant reduction of gadolinium-enhancing lesions compared to baselineAdditional data show improved...
May 18, 2020 07:30 ET | Source: Biogen Inc.

New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients

Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adultsThe longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ages...
April 27, 2020 16:06 ET | Source: Biogen Inc.

Biogen Prices $3.0 Billion of Senior Unsecured Notes

CAMBRIDGE, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the pricing of two series of senior unsecured notes for an aggregate principal amount of $3.0 billion....
April 20, 2020 17:45 ET | Source: Biogen Inc.

Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics

Continued to improve absolute environmental performance across energy, water and waste metrics while growing the business in 2019; has remained carbon neutral for six years in a rowAdvanced health...